PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED STAGE III

PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED STAGE III was reported 18 times

PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED STAGE III is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Topoisomerase Inhibitor [EPC] 5 0.0001
1 Alkylating Drug [EPC] 7 0.0000
2 CD20-directed Cytolytic Antibody [EPC] 6 0.0000
3 Folate Analog Metabolic Inhibitor [EPC] 8 0.0000
4 Corticosteroid [EPC] 7 0.0000
5 Dihydropyridine Calcium Channel Blocker [EPC] 1 0.0000
6 HMG-CoA Reductase Inhibitor [EPC] 1 0.0000
7 Insulin Analog [EPC] 1 0.0000
8 Loop Diuretic [EPC] 1 0.0000
9 Tumor Necrosis Factor Blocker [EPC] 1 0.0000